Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
Completed
- Conditions
- Hypertension
- Interventions
- Procedure: Home Blood Pressure
- Registration Number
- NCT03254914
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Brief Summary
The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or more concomitant antihypertensive agents including fimasartan
- Detailed Description
A multi-center, cluster-randomized, prospective, observational study
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3554
Inclusion Criteria
- Subjects who voluntarily signed informed consent for participating in this clinical study
- Male and female over the age of 19
- Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan
Exclusion Criteria
- Renal dialysis patients.
- Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor.
- Severe renal disorder
- Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Medical history with hypersensitivity to Fimasartan
- Pregnant women or lactating female.
- Participate in another clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Test Site Home Blood Pressure Measure Clinic Blood Pressure and Home Blood Pressure
- Primary Outcome Measures
Name Time Method Rate of reaching target blood pressure 12 weeks after treatment Rate of reaching target blood pressure after treatment for 12 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Seoul national university hospital
🇰🇷Seoul, Korea, Republic of